Latest Information Update: 07 Dec 2001
At a glance
- Originator Innogenetics
- Class Cytokines
- Mechanism of Action Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Fracture
Most Recent Events
- 07 Dec 2001 Discontinued-Preclinical for Fracture in Belgium (Unknown route)
- 07 Sep 1998 No-Development-Reported for Fracture in Belgium (Unknown route)
- 16 Oct 1996 New profile